Section 2 - Composition, Information on Ingredients

CAS#	Chemical Name	Percent	EINECS/ELINCS
79-06-1	Acrylamide	>94.0	201-173-7
110-26-9	Methylenediacrylamide	<6.0	203-750-9

Section 3 - Hazards Identification

Appearance: white solid.
Warning! Acrylamide may cause nervous system damage. Acrylamide caused cancer and male reproductive disorders in laboratory animal tests. Acrylamide may polymerize explosively if heated to 183°F (84°C). Acrylamide may form explosive dust-air mixtures. Harmful if swallowed, inhaled, or absorbed through the skin. Causes eye irritation. May cause allergic skin reaction. Cancer suspect agent. Light sensitive. Air sensitive. Hygroscopic (absorbs moisture from the air).
Target Organs: Eyes, nervous system, reproductive system, skin.


Potential Health Effects
Eye: Causes eye irritation. Acrylamide can be absorbed through the eyes and overexposure will produce the signs and symptoms of neurotoxicity described below.
Skin: May cause skin sensitization, an allergic reaction, which becomes evident upon re-exposure to this material. Acrylamide is readily absorbed through unbroken skin and can cause nervous system effects (neurotoxicity). These effects can result from a single overexposure but are more likely after repeated exposures to small amounts over a period of days or weeks. Signs and symptoms of overexposure include increased sweating of the hands and feet, numbness, tingling and weakness in the extremities, unsteady gait and decreased reflexes. If the exposure route is dermal, the symptoms may be preceded by peeling and redness of the skin at the areas of exposure, normally the hands and feet.
Ingestion: Harmful if swallowed. May cause central, peripheral, and autonomic nervous system effects. Central nervous system effects, which appear to predominate in acute cases, are characterized by abnormal fatigue, memory difficulties, and dizziness. Peripheral neuropathy symptoms, which are more common with repeated low-dose exposure or following a latency period of up to several weeks after acute exposure can include: muscular weakness, paresthesia, numbness in hands, feet, lower legs, and lower arms, unsteadiness, and difficulties in walking and standing. Autonomic nervous system involvement is indicated by excessive sweating, peripheral vasodilation and difficulties in micturation and defecation.
Inhalation: Acrylamide tends to sublime (go directly from solid to vapor form) which may lead to inhalation exposure. Acrylamide can be absorbed through the lungs and overexposure will produce the signs and symptoms of neurotoxicity described above.
Chronic: Prolonged or repeated skin contact may cause dermatitis. May cause cancer according to animal studies. Adverse reproductive effects have been reported in animals. Prolonged or repeated exposure affects the nervous system.

Section 4 - First Aid Measures

Eyes: In case of contact, immediately flush eyes with plenty of water for a t least 15 minutes. Get medical aid.
Skin: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical aid immediately. Wash clothing before reuse.
Ingestion: If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician: Either acute or chronic exposure may lead to weak or absent reflexes, positive Romberg's sign, loss of vibration and position senses and numbness and tingling of the limbs. An early sign of toxic effects is peeling of the skin of the fingertips.
Antidote: Pyridoxine (vitamin B6), pyruvate, and N-acetylcysteine have been used to reduce the toxicity of acrylamide in experimental studies, but are unproven.

Section 5 - Fire Fighting Measures

General Information: Containers can build up pressure if exposed to heat and/or fire. As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Use water spray to keep fire-exposed containers cool. Dust can be an explosion hazard when exposed to heat or flame. Combustible solid. Approach fire from upwind to avoid hazardous vapors and toxic decomposition products. Fight fire from maximum distance or use unmanned hose holders or monitor nozzles.
Extinguishing Media: Use water spray, dry chemical, carbon dioxide, or chemical foam.
Flash Point: Not applicable.
Autoignition Temperature: 464 deg F ( 240.00 deg C)
Explosion Limits, Lower:Not available.
Upper: Not available.
NFPA Rating: (estimated) Health: 2; Flammability: 2; Instability: 2

Section 6 - Accidental Release Measures

General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks: Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Remove all sources of ignition. Isolate area and deny entry. Provide ventilation.

Section 7 - Handling and Storage

Handling: Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Minimize dust generation and accumulation. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Keep away from heat, sparks and flame. Do not ingest or inhale. Use only in a chemical fume hood.
Storage: Keep away from heat, sparks, and flame. Do not store in direct sunlight. Keep from contact with oxidizing materials. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep away from acids. Do not store near alkaline substances. Keep away from polymerization catalysts. Should not be exposed to temperatures above 122°F (50°C).

Section 8 - Exposure Controls, Personal Protection

Engineering Controls: Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels below recommended exposure limits. Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Utilize a closed system process where feasible.
Exposure Limits

Chemical Name	ACGIH	NIOSH	OSHA - Final PELs
Acrylamide	0.03 mg/m3 TWA; Skin - potential significant contribution to overall exposure by the cutaneous r oute	0.03 mg/m3 TWA 60 mg/m3 IDLH	0.3 mg/m3 TWA
Methylenediacrylamide	none listed	none listed	none listed

OSHA Vacated PELs: Acrylamide: 0.03 mg/m3 TWA Methylenediacrylamide: No OSHA Vacated PELs are listed for this chemical.
Personal Protective Equipment
Eyes: Wear chemical splash goggles.
Skin: Wear appropriate protective gloves to prevent skin exposure.
Clothing: Wear appropriate protective clothing to prevent skin exposure.
Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - Physical and Chemical Properties

Physical State: Solid
Appearance: white
Odor: Odorless.
pH: Not available.
Vapor Pressure: .007 mm Hg @ 25 deg C
Vapor Density: 2.45 (air=1)
Evaporation Rate:Not available.
Viscosity: Not available.
Boiling Point: 125 deg C @ 25 mm Hg
Freezing/Melting Point:83 - 85 deg C (decomposes
Decomposition Temperature:84 deg C
Solubility: Soluble.
Specific Gravity/Density:1.122 @ 30°C
Molecular Formula:C3H5NO
Molecular Weight:71.08

Section 10 - Stability and Reactivity

Chemical Stability: Stable. However may polymerize explosively if heated to the melting point. May polymerize on exposure to light.
Conditions to Avoid: Light, ignition sources, moisture, exposure to air, heat.
Incompatibilities with Other Materials: Metals, oxidizing agents, reducing agents, acids, bases, peroxides.
Hazardous Decomposition Products: Carbon monoxide, oxides of nitrogen, carbon dioxide, ammonia and/or derivatives, hydrogen gas.
Hazardous Polymerization: May occur.

Section 11 - Toxicological Information

RTECS#:      
CAS# 79-06-1: AS3325000      
CAS# 110-26-9: AS3678000
LD50/LC50:
CAS# 79-06-1:
     Draize test, rabbit, eye: 100 mg/24H Moderate;
     Draize test, rabbit, skin: 50 mg/3D Mild;
     Draize test, rabbit, skin: 500 mg/24H Mild;
     Oral, mouse: LD50 = 107 mg/kg;
     Oral, rabbit: LD50 = 150 mg/kg;
     Oral, rat: LD50 = 124 mg/kg;
     Skin, rabbit: LD50 = 1680 uL/kg;
     Skin, rat: LD50 = 400 mg/kg;
CAS# 110-26-9:
     Oral, mouse: LD50 = 380 mg/kg;
     Oral, rat: LD50 = 390 mg/kg;
Carcinogenicity:
CAS# 79-06-1:

• ACGIH: A3 - Confirmed animal carcinogen with unknown relevance to humans
  
• California: carcinogen, initial date 1/1/90
  
• NTP: Suspect carcinogen
  
• IARC: Group 2A carcinogen